GSK PLC (GSK)
33.96
+0.26
(+0.77%)
USD |
NYSE |
Nov 22, 16:00
34.14
+0.18
(+0.53%)
After-Hours: 20:00
GSK Cash from Financing (Quarterly): -1.718B for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -1.718B |
| June 30, 2024 | -1.991B |
| March 31, 2024 | -1.344B |
| December 31, 2023 | -4.425B |
| September 30, 2023 | -2.235B |
| June 30, 2023 | 27.30M |
| March 31, 2023 | -386.53M |
| December 31, 2022 | -1.524B |
| September 30, 2022 | -1.840B |
| June 30, 2022 | -6.313B |
| March 31, 2022 | 10.70B |
| December 31, 2021 | -3.802B |
| September 30, 2021 | -1.857B |
| June 30, 2021 | -2.885B |
| March 31, 2021 | -1.897B |
| December 31, 2020 | -2.722B |
| September 30, 2020 | -5.718B |
| June 30, 2020 | -3.216B |
| March 31, 2020 | -1.348B |
| December 31, 2019 | -3.482B |
| September 30, 2019 | -2.426B |
| June 30, 2019 | -1.211B |
| March 31, 2019 | 4.769B |
| December 31, 2018 | -4.430B |
| September 30, 2018 | -2.087B |
| Date | Value |
|---|---|
| June 30, 2018 | -1.614B |
| March 31, 2018 | -393.51M |
| December 31, 2017 | -4.150B |
| September 30, 2017 | -925.52M |
| June 30, 2017 | -1.294B |
| March 31, 2017 | -1.869B |
| December 31, 2016 | -2.817B |
| September 30, 2016 | -2.276B |
| June 30, 2016 | -1.689B |
| March 31, 2016 | -1.880B |
| December 31, 2015 | -1.345B |
| September 30, 2015 | -3.196B |
| June 30, 2015 | -3.613B |
| March 31, 2015 | -2.701B |
| December 31, 2014 | -2.662B |
| September 30, 2014 | -253.37M |
| June 30, 2014 | -1.677B |
| March 31, 2014 | -4.284B |
| December 31, 2013 | -2.595B |
| September 30, 2013 | -1.762B |
| June 30, 2013 | -3.197B |
| March 31, 2013 | -2.260B |
| December 31, 2012 | -1.603B |
| September 30, 2012 | -1.909B |
| June 30, 2012 | 158.84M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.313B
Minimum
Jun 2022
10.70B
Maximum
Mar 2022
-1.899B
Average
-1.944B
Median
Cash from Financing (Quarterly) Benchmarks
| AstraZeneca PLC | -4.131B |
| Merck & Co Inc | -2.425B |
| Pfizer Inc | -4.636B |
| Sanofi SA | -- |
| Moderna Inc | 11.00M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.885B |
| Cash from Investing (Quarterly) | -926.64M |
| Free Cash Flow | 6.053B |
| Free Cash Flow Per Share (Quarterly) | 0.8449 |
| Free Cash Flow to Equity (Quarterly) | 1.689B |
| Free Cash Flow to Firm (Quarterly) | 1.913B |
| Free Cash Flow Yield | 8.64% |